Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder's Warrants

Accesswire December 8, 2023

Bionxt Solutions Announces Convertible Debenture and Interest Settlement

Accesswire November 24, 2023

BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament

Accesswire November 20, 2023

BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program

Accesswire November 15, 2023

BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis

Accesswire November 13, 2023

BioNxt Solutions Reports on Barcelona CPHI Conference

Accesswire November 6, 2023

BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement

Accesswire October 27, 2023

BioNxt Solutions Announces Change of Directors

Accesswire October 3, 2023

Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

Accesswire September 28, 2023

BioNxt Solutions Announces Non-Brokered Private Placement

Accesswire August 4, 2023

BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease

Accesswire August 2, 2023

BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease

Accesswire May 15, 2023

BioNxt Successfully Completes Pilot Study for Contract Development Customer

Accesswire May 9, 2023

BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company

Accesswire April 24, 2023

BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity

Accesswire April 17, 2023

BioNxt Reports on Enteric Coating Drug Delivery Program

Accesswire April 14, 2023

BioNxt Solutions Announces Closing of Non-Brokered Private Placement and Grant of Stock Options

Accesswire April 3, 2023

BioNxt Solutions Closes First Tranche of Financing

Accesswire March 27, 2023

Bionxt Solutions Announces Non-Brokered Private Placement

Accesswire March 10, 2023

BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology

Accesswire March 7, 2023